Previous 10 | Next 10 |
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2019 Results Earnings Conference Call May 1, 2019, 08:00 AM ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Pablo Lapuerta - Executive Vice Presiden...
Lexicon Pharmaceuticals ( LXRX ) Q1 results : Revenues: $9.2M (-63.8%); Net product revenue: $6.7M (+21.8%); Collaborative agreements: $2.4M (-87.9%); Royalties and other revenue: $0.04M (-50.0%). More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and comme...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q1 GAAP EPS of -$0.21 in-line. More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
THE WOODLANDS, Texas, May 01, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March 31, 2019. “XERMELO net sales grew more than 20% in the first quarter of 2019 ve...
Precipio (NASDAQ: PRPO ) +38% on first major international services contract. More news on: Precipio, Inc., Innovate Biopharmaceuticals, Inc., Changyou.com Limited, Stocks on the move, Read more ...
Gainers: LXRX +12.2% . MGI +3.6% . OMF +2.7% . LAZ +1.8% . AMC +1.6% . More news on: Lexicon Pharmaceuticals, Inc., MoneyGram International, Inc., OneMain Holdings, Inc., Stocks on the move, Read more ...
PARIS and THE WOODLANDS, Texas, April 26, 2019 (GLOBE NEWSWIRE) -- The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon (Nasdaq: LXRX). Zynquista is now approved in the European Union, at once-daily doses of 200 ...
THE WOODLANDS, Texas, April 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a...
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securitie...
Once again the FDA has shown that when it comes to new therapies for diabetes, particularly Type 1 diabetes, the agency believes in an abundance (perhaps an overabundance) of caution. To that point, Sanofi ( SNY ) and Lexicon ( LXRX ) announced on Friday March 22 that the FDA rejected ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...